Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Comment by Garp1on Apr 10, 2018 2:34pm

97 Views

Post# 27861093

RE:RE:RE:RE:RE:RE:RE:RE:Volume and consideration before take-off.....

Right now, I don't believe Tanguay would be able to stop a 20$ to 25$ takeover bid. The best He could hope for, would be to find a better suiter with the time the poison pill would buy him.

An offer at almost 2.5 times the current share price and given management ultra conservative approach with no commitment to perceived or tangible sales objectives, why wait another 1 to 2 years in this risky market.

You and I might recognise that management is highly focused on the success of TH but in the end market forces will decide the direction this company will take.

Bullboard Posts

Visionstate set to leverage success in the U.S. market